Zobrazeno 1 - 10 of 16 pro vyhledávání: '"van Zeijl MCT"'
2
Akademický článek
Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.
Autor: van Zeijl MCT; Scientific Department, Dutch Institute for Clinical Auditing.; Department of Medical Oncology, Leiden University Medical Centre., van Breeschoten J; Scientific Department, Dutch Institute for Clinical Auditing.; Department of Medical Oncology, Amsterdam UMC-location VUmc, Cancer Center Amsterdam., de Wreede LC; Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands., Wouters MWJM; Scientific Department, Dutch Institute for Clinical Auditing.; Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands.; Department of Surgical Oncology, Netherlands Cancer Institute., Hilarius DL; Department of Pharmacy, Rode Kruis Ziekenhuis, Beverwijk., Blank CU; Divisions of Medical Oncology and Molecular Oncology & Immunology, Netherlands Cancer Institute.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam., Aarts MJB; Department of Medical Oncology, GROW-School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Centre Sittard, Sittard-Geleen., de Groot JWB; Isala Oncology Center, Isala, Zwolle., Hospers GAP; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Centre., Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Enschede., van Rijn RS; Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden., Stevense-den Boer MA; Department of Internal Medicine, Amphia Hospital, Breda., van der Veldt AAM; Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Centre, Rotterdam., Vreugdenhil G; Department of Internal Medicine, Maxima Medical Centre, Eindhoven., Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen., Suijkerbuijk KPM; Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands., Haanen JBAG; Department of Medical Oncology, Leiden University Medical Centre.; Divisions of Medical Oncology and Molecular Oncology & Immunology, Netherlands Cancer Institute.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam., van den Eertwegh AJM; Department of Medical Oncology, Amsterdam UMC-location VUmc, Cancer Center Amsterdam.
Publikováno v: Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2023 Jun 01; Vol. 46 (5), pp. 197-204. Date of Electronic Publication: 2023 Apr 28.
Zobrazit plný text záznamu
3
Akademický článek
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.
Autor: Ismail RK; Dutch Institute for Clinical Auditing, Leiden.; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht.; Medicines Evaluation Board, Utrecht., Suijkerbuijk KPM; Department of Medical Oncology, University Medical Centre Utrecht, Utrecht., de Boer A; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht.; Medicines Evaluation Board, Utrecht., van Dartel M; Medicines Evaluation Board, Utrecht., Hilarius DL; Department of Pharmacy, Rode Kruis Ziekenhuis, Beverwijk., Pasmooij AMG; Medicines Evaluation Board, Utrecht., van Zeijl MCT; Department of Medical Oncology, Leiden University Medical Centre, Leiden., Aarts MJB; Department of Medical Oncology, Grow School for Oncology and Developmental Biology Maastricht University Medical Centre, Maastricht., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Centre Sittard, Sittard-Geleen., Blank CU; Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Amsterdam., Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen., de Groot JWB; Department of Medical Oncology, Isala, Zwolle., Haanen JBAG; Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Amsterdam., Hospers GAP; Department of Medical Oncology, University Medical Centre Groningen, Groningen., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Centre, Leiden., Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Enschede., van Rijn RS; Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden., van der Veldt AAM; Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Centre, Rotterdam., Vreugdenhil A; Department of Internal Medicine, Maxima Medical Centre, Eindhoven., Westgeest H; Department of Internal Medicine, Amphia Hospital, Breda., van den Eertwegh AJ; Department of Medical Oncology, Amsterdam University Medical Center, Amsterdam., Wouters MWJM; Dutch Institute for Clinical Auditing, Leiden.; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan, Amsterdam.; Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands.
Publikováno v: Melanoma research [Melanoma Res] 2022 Dec 01; Vol. 32 (6), pp. 460-468. Date of Electronic Publication: 2022 Sep 05.
Zobrazit plný text záznamu
4
Akademický článek
Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice.
Autor: van Zeijl MCT; Scientific Department, Dutch Institute for Clinical Auditing, Leiden, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., van den Eertwegh AJM; Department of Medical Oncology, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands., Wouters MWJM; Scientific Department, Dutch Institute for Clinical Auditing, Leiden, The Netherlands.; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands., de Wreede LC; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands., Aarts MJB; Department of Medical Oncology, Maastricht University Medical Center+, Maastricht, The Netherlands., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands., de Groot JB; Department of Medical Oncology, Isala Oncology Center, Zwolle, The Netherlands., Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Piersma D; Department of Internal Medicine, Medical Spectrum Twente, Enschede, The Netherlands., van Rijn RS; Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Suijkerbuijk KPM; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Ten Tije AJ; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands., van der Veldt AAM; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Vreugdenhil G; Department of Internal Medicine, Maxima Medical Center, Eindhoven, The Netherlands., van der Hoeven JJM; Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands., Haanen JBAG; Divisions of Medical Oncology and Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Publikováno v: International journal of cancer [Int J Cancer] 2022 Jan 15; Vol. 150 (2), pp. 317-326. Date of Electronic Publication: 2021 Oct 02.
Zobrazit plný text záznamu
5
Akademický článek
Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry.
Autor: Jochems A; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: a.jochems@lumc.nl., Bastiaannet E; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Surgical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Aarts MJB; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, the Netherlands., van Akkooi ACJ; Department of Surgical Oncology, Netherlands Cancer Institute- Antoni van Leeuwenhoek hospital, Amsterdam, the Netherlands., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Center, Sittard, the Netherlands., Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., van den Eertwegh AJM; Department of Medical Oncology, Amsterdam UMC, location VU Medical Center, Amsterdam, the Netherlands., de Glas NG; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., de Groot JWB; Isala Oncology Center, Zwolle, the Netherlands., Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute- Antoni van Leeuwenhoek hospital, Amsterdam, the Netherlands., Hospers GAP; Department of Medical Oncology, Groningen University Medical Center, University of Groningen, Groningen, the Netherlands., van der Hoeven JJM; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Piersma D; Department of Medical Oncology, Medisch Spectrum Twente, Enschede, the Netherlands., van Rijn RS; Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, the Netherlands., Suijkerbuijk KPM; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands., Ten Tije AJ; Department of Medical Oncology, Amphia hospital, Breda, the Netherlands., van der Veldt AAM; Departments of Medical Oncology and Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands., Vreugdenhil G; Department of Medical Oncology, Maxima Medical Center, Eindhoven, the Netherlands., van Zeijl MCT; Scientific bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Wouters MWJM; Department of Surgical Oncology, Netherlands Cancer Institute- Antoni van Leeuwenhoek hospital, Amsterdam, the Netherlands; Scientific bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.
Publikováno v: Journal of geriatric oncology [J Geriatr Oncol] 2021 Sep; Vol. 12 (7), pp. 1031-1038. Date of Electronic Publication: 2021 May 19.
Zobrazit plný text záznamu
6
Akademický článek
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.
Autor: van der Kooij MK; Leiden University Medical Center, Leiden, the Netherlands (M.K.V., O.M.D., E.K.)., Suijkerbuijk KPM; University Medical Center Utrecht, Utrecht, the Netherlands (K.P.S.)., Aarts MJB; Maastricht University Medical Center, Maastricht, the Netherlands (M.J.A.)., van den Berkmortel FWPJ; Zuyderland Medical Center, Sittard-Geleen, the Netherlands (F.W.V.)., Blank CU; Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands (C.U.B., J.B.H.)., Boers-Sonderen MJ; Radboud University Medical Center, Nijmegen, the Netherlands (M.J.B.)., van Breeschoten J; Dutch Institute for Clinical Auditing, Leiden, and Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands (J.V.)., van den Eertwegh AJM; Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands (A.J.V.)., de Groot JWB; Isala Oncology Center, Isala, Zwolle, the Netherlands (J.W.B.)., Haanen JBAG; Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands (C.U.B., J.B.H.)., Hospers GAP; University Medical Center Groningen, Groningen, the Netherlands (G.A.H.)., Piersma D; Medisch Spectrum Twente, Enschede, the Netherlands (D.P.)., van Rijn RS; Medical Center Leeuwarden, Leeuwarden, the Netherlands (R.S.V.)., Ten Tije AJ; Amphia Ziekenhuis, Breda, the Netherlands (A.J.T.)., van der Veldt AAM; Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands (A.A.V.)., Vreugdenhil G; Maxima Medical Center, Veldhoven, the Netherlands (G.V.)., van Zeijl MCT; Dutch Institute for Clinical Auditing, Leiden, the Netherlands (M.C.V.)., Wouters MWJM; Dutch Institute for Clinical Auditing, Leiden, and Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands (M.W.W.)., Dekkers OM; Leiden University Medical Center, Leiden, the Netherlands (M.K.V., O.M.D., E.K.)., Kapiteijn E; Leiden University Medical Center, Leiden, the Netherlands (M.K.V., O.M.D., E.K.).
Publikováno v: Annals of internal medicine [Ann Intern Med] 2021 May; Vol. 174 (5), pp. 641-648. Date of Electronic Publication: 2021 Feb 16.
Zobrazit plný text záznamu
7
Akademický článek
Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry.
Autor: van Zeijl MCT; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden, 2333AA, the Netherlands; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333ZA, the Netherlands., de Wreede LC; Department of Biomedical Data Sciences, Leiden University Medical Center, Einthovenweg 20, Leiden, 2333ZC, the Netherlands., van den Eertwegh AJM; Department of Medical Oncology, Amsterdam UMC, Location VU Medical Center (VUmc), Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, 1081 HV, the Netherlands., Wouters MWJM; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden, 2333AA, the Netherlands; Department of Surgical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066CX, the Netherlands., Jochems A; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden, 2333AA, the Netherlands; Department of Medical Oncology, Haaglanden Medisch Centrum, Lijnbaan 32, Den Haag, 2512VA, the Netherlands., Schouwenburg MG; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden, 2333AA, the Netherlands., Aarts MJB; Department of Medical Oncology, Maastricht University Medical Center, P. Debyelaan 25, Maastricht, 6229 HX, the Netherlands., van Akkooi ACJ; Department of Surgical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066CX, the Netherlands., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Center, Dr. H. van der Hoffplein 1, Sittard-Geleen, 6162BG, the Netherlands., de Groot JWB; Department of Medical Oncology, Isala Clinics, Dokter van Heesweg 2, Zwolle, 8025AB, the Netherlands., Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713GZ, the Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333ZA, the Netherlands., Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, Enschede, 7512KZ, the Netherlands., van Rijn RS; Department of Internal Medicine, Medical Center Leeuwarden, Henri Dunantweg 2, Leeuwarden, 8934AD, the Netherlands., Suijkerbuijk KPM; Department of Medical Oncology, University Medical Center Utrecht, Cancer Center, Heidelberglaan 100, Utrecht, 3584CX, the Netherlands., Ten Tije AJ; Department of Internal Medicine, Amphia Hospital, Molengracht 21, Breda, 4818CK, the Netherlands., van der Veldt AAM; Department of Medical Oncology, Erasmus MC Cancer Institute, 's-Gravendijkwal 230, Rotterdam, 3015CE, the Netherlands., Vreugdenhil G; Department of Internal Medicine, Maxima Medical Center, De Run 4600, Eindhoven, 5504DB, the Netherlands., van der Hoeven JJM; Department of Medical Oncology, Radboudumc, Geert Grooteplein Zuid 10, Nijmegen, 6525GA, the Netherlands., Haanen JBAG; Divisions of Medical Oncology and Molecular Oncology & Immunology, the Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066CX, the Netherlands. Electronic address: j.haanen@nki.nl.
Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Feb; Vol. 144, pp. 242-251. Date of Electronic Publication: 2020 Dec 26.
Zobrazit plný text záznamu
8
Akademický článek
Real-world outcomes of advanced melanoma patients not represented in phase III trials.
Autor: van Zeijl MCT; Scientific department, Dutch Institute for Clinical Auditing, Leiden, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Ismail RK; Scientific department, Dutch Institute for Clinical Auditing, Leiden, The Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.; Medicines Evaluation Board, Utrecht, The Netherlands., de Wreede LC; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands., van den Eertwegh AJM; Department of Medical Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., de Boer A; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.; Medicines Evaluation Board, Utrecht, The Netherlands., van Dartel M; Medicines Evaluation Board, Utrecht, The Netherlands., Hilarius DL; Department of Pharmacy, Red Cross Hospital, Beverwijk, The Netherlands., Aarts MJB; Department of Medical Oncology, Maastricht University Medical Center+, Maastricht, The Netherlands., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands., Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., de Groot JB; Isala Oncology Center, Isala, Zwolle, The Netherlands., Hospers GAP; Department of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands., van Rijn RS; Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Suijkerbuijk KPM; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Ten Tije AJ; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands., van der Veldt AAM; Departments of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands., Vreugdenhil G; Department of Internal Medicine, Maxima Medical Center, Eindhoven, The Netherlands., Haanen JBAG; Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Wouters MWJM; Scientific department, Dutch Institute for Clinical Auditing, Leiden, The Netherlands.; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Publikováno v: International journal of cancer [Int J Cancer] 2020 Dec 15; Vol. 147 (12), pp. 3461-3470. Date of Electronic Publication: 2020 Jul 04.
Zobrazit plný text záznamu
9
Akademický článek
Lower risk of severe checkpoint inhibitor toxicity in more advanced disease.
Autor: Verheijden RJ; Department of Medical Oncology, UMC Utrecht, Utrecht, The Netherlands., May AM; University Medical Center Utrecht, Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde, Utrecht, The Netherlands., Blank CU; Department of Medical Oncology and Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Veldt AAM; Departments of Medical Oncology and Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands., Boers-Sonderen MJ; Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands., Aarts MJB; Department of Medical Oncology, Maastricht UMC+, Maastricht, The Netherlands., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Centre Sittard-Geleen, Sittard-Geleen, The Netherlands., van den Eertwegh AJM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands., de Groot JWB; Oncology Center Isala, Isala Zwolle, Zwolle, The Netherlands., van der Hoeven JJM; Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands., Hospers GAP; Department of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands., Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands., van Rijn RS; Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands., Ten Tije AJ; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands., Vreugdenhil G; Department of Internal Medicine, Maxima Medical Centre, Eindhoven, The Netherlands., van Zeijl MCT; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands; Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, The Netherlands., Wouters MWJM; Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, The Netherlands; Department of Medical and Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Haanen JBAG; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands, Amsterdam, The Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Suijkerbuijk KPM; Department of Medical Oncology, UMC Utrecht, Utrecht, The Netherlands. Electronic address: K.Suijkerbuijk@umcutrecht.nl.
Publikováno v: ESMO open [ESMO Open] 2020 Nov; Vol. 5 (6), pp. e000945.
Zobrazit plný text záznamu
10
Akademický článek
Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
Autor: van Zeijl MCT; Scientific department, Dutch Institute for Clincal Auditing.; Departments of Department of Medical Oncology, Leiden University Medical Centre., Haanen JBAG; Divisions of Medical Oncology and Molecular Oncology and Immunology, Netherlands Cancer Institute., Wouters MWJM; Scientific department, Dutch Institute for Clincal Auditing.; Department of Surgical Oncology, Netherlands Cancer Institute., de Wreede LC; Biomedical Data Sciences, Leiden University Medical Centre, Leiden., Jochems A; Scientific department, Dutch Institute for Clincal Auditing.; Department of Medical Oncology, Haaglanden Medisch Centrum, Den Haag., Aarts MJB; Department of Medical Oncology, Maastricht University Medical Centre, Maastricht., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Centre Sittard, Sittard-Geleen., de Groot JWB; Isala Oncology Center, Zwolle., Hospers GAP; Department of Medical Oncology, University Medical Centre Groningen, Groningen., Kapiteijn EW; Departments of Department of Medical Oncology, Leiden University Medical Centre., Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Enschede., van Rijn RS; Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden., Suijkerbuijk KPM; Department of Medical Oncology, University Medical Centre Utrecht, Utrecht., Ten Tije AJ; Department of Internal Medicine, Amphia Hospital, Breda., van der Veldt AAM; Department of Medical Oncology, Erasmus Medical Centre, Rotterdam., Vreugdenhil G; Department of Internal Medicine, Maxima Medical Centre, Eindhoven., van der Hoeven KJM; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., van den Eertwegh AJM; Department of Medical Oncology, Amsterdam UMC-location VUmc, Cancer Center Amsterdam, Amsterdam.
Publikováno v: Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2020 Oct; Vol. 43 (8), pp. 256-264.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje